Posts Tagged ‘clinical trials’

Valuing the good, the bad and the ugly

Author: David Kent, 08/29/17

As with all of my posts that relate to anything that might end up being a medical treatment, it is important to be very clear that I am scientist and not a physician.  My comments are my own opinion and based on my experience as a stem cell biologist over the last 10+ years. This…Read more

Right Turn: Clinical trials – one solution to unapproved stem cell treatments

Author: Stacey Johnson, 07/14/17

I’ve been thinking about unapproved stem cell treatments a lot recently. First, I read this article that hailed the arrival of stem cell treatments in a small community in western Canada. There were many statements in the article that concerned me, but I only addressed a few major ones in my letter to the editor….Read more

Major League Baseball Pitchers and “Stem Cell” therapy

Author: David Kent, 04/18/17

With the Toronto Blue Jays* off to a terrible start, I was almost dissuaded from reading anything about baseball, until I happened upon the following article: “Stem-cell therapy is poised to disrupt the Tommy John epidemic in baseball.” First, I had to do my standard “fake news” check by triangulating the sources, readings, etc., but…Read more

Why do stroke regenerative therapies fail to reach the clinic?

Author: Samantha Payne, 03/07/17

The author of the popular Seven Habits of Highly Effective People book, Steven R. Covery, said “strength lies in differences, not in similarities.” While this may be helpful advice for improving your personal life, researchers are learning that differences in preclinical studies are weakening the ability to translate effective therapies to the clinic. While one…Read more

Learning About Industry from the Insiders at Phacilitate Cell and Gene Therapy World 2017

Author: Nicole Forgione, 02/08/17

In January, I attended Phacilitate’s Cell and Gene Therapy World in Miami, Florida. At this meeting industry leaders from around the world gather to discuss manufacturing, regulation and adoption of cell and gene therapies (C&GT). This was my first industry-focused conference, and it was a great chance to learn the ropes from experienced players in…Read more

Insights from CGTW16 – Part 3: Clinical trials, health economics and regulatory affairs

Author: Guest, 12/01/16

Amin Adibi is a biomedical engineer and a research assistant at the University of British Columbia. His areas of interest include cell manufacturing and bioprocess optimization, clinical translation of cellular therapies, health outcomes and cost-effectiveness modelling. Amin has an MSc degree from University of Calgary, where he focused on developing adjuvant MSC-based therapies for brain…Read more

Right Turn: Finding a treatment for vision loss is looking up

Author: Stacey Johnson, 10/21/16

October 13, 2016 was World Sight Day and the month of October is dedicated to blindness and vision loss awareness. No doubt that is why the California Institute for Regenerative Medicine (CIRM) recently shared the third installment in its Stem Cells in Your Face series. In the video below, narrator Kevin McCormack, whose day job…Read more

The stem cell therapy’s obstacle course

Author: Jovana Drinjakovic, 08/25/16

Science fiction became real life in September 2014, when a team of eye surgeons in Japan transplanted a body part, grown entirely in a dish, into the eye of a patient suffering from an eye disease. The retinal graft came from the patient’s skin cells, raising hopes that one day our own bodies could be…Read more

Update from the Clinic: May

Author: Mark Curtis, 06/30/16

Welcome to your update from the clinic for the month of May. Long-standing industry pioneer StemCells, Inc. decided to wind down its operations after a failed Phase 2 study in spinal cord injury. Aduro Biotech also saw a failure with its GVAX product in pancreatic cancer. Kite continues to deliver on its regulatory strategy, announcing…Read more

Right Turn: Canadian procedure stops MS in some patients

Author: Stacey Johnson, 06/10/16

In 2002, Jennifer Molson received a stem cell transplant for her aggressive form of multiple sclerosis (MS), diagnosed six years earlier when she was 21. This unique treatment for MS – transplanting blood stem cells from a patient’s own bone marrow to replace the diseased immune system – is now the subject of an article…Read more